Cerevel Therapeutics Holdings Analysis
Cerevel Therapeutics Holdings is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Cerevel Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Cerevel Therapeutics Holdings is worth, separate from its market price. There are two main types of Cerevel Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cerevel Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cerevel Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Cerevel |
Cerevel Stock Analysis Notes
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.73. Cerevel Therapeutics had not issued any dividends in recent years. The entity had 1:1 split on the 28th of October 2020. Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 258 people. For more info on Cerevel Therapeutics Holdings please contact MBA Renaud at 844 304 2048 or go to https://www.cerevel.com.Cerevel Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cerevel Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cerevel Therapeutics Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Cerevel Therapeutics is not yet fully synchronised with the market data | |
| Cerevel Therapeutics has some characteristics of a very speculative penny stock | |
| Cerevel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (432.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cerevel Therapeutics Holdings currently holds about 531.21 M in cash with (342.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.58. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies |
Cerevel Therapeutics Upcoming and Recent Events
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cerevel Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.19 B.Cerevel Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cerevel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cerevel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cerevel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cerevel Therapeutics Outstanding Bonds
Cerevel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cerevel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cerevel bonds can be classified according to their maturity, which is the date when Cerevel Therapeutics Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US156700BD72 Corp BondUS156700BD72 | View | |
| CenturyLink 765 percent Corp BondUS156700AT34 | View | |
| CenturyLink 5625 percent Corp BondUS156700AZ93 | View |
Cerevel Therapeutics Technical and Predictive Indicators
| Risk Adjusted Performance | 0.0621 | |||
| Market Risk Adjusted Performance | 12.09 | |||
| Mean Deviation | 0.7719 | |||
| Semi Deviation | 0.9382 | |||
| Downside Deviation | 1.05 | |||
| Coefficient Of Variation | 1413.27 | |||
| Standard Deviation | 1.2 | |||
| Variance | 1.44 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0743 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 12.08 | |||
| Maximum Drawdown | 6.4 | |||
| Value At Risk | (1.59) | |||
| Potential Upside | 1.91 | |||
| Downside Variance | 1.11 | |||
| Semi Variance | 0.8802 | |||
| Expected Short fall | (1.02) | |||
| Skewness | 0.1629 | |||
| Kurtosis | 4.99 |
| Risk Adjusted Performance | 0.0621 | |||
| Market Risk Adjusted Performance | 12.09 | |||
| Mean Deviation | 0.7719 | |||
| Semi Deviation | 0.9382 | |||
| Downside Deviation | 1.05 | |||
| Coefficient Of Variation | 1413.27 | |||
| Standard Deviation | 1.2 | |||
| Variance | 1.44 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0743 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 12.08 | |||
| Maximum Drawdown | 6.4 | |||
| Value At Risk | (1.59) | |||
| Potential Upside | 1.91 | |||
| Downside Variance | 1.11 | |||
| Semi Variance | 0.8802 | |||
| Expected Short fall | (1.02) | |||
| Skewness | 0.1629 | |||
| Kurtosis | 4.99 |
About Cerevel Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cerevel Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cerevel shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Cerevel Therapeutics. By using and applying Cerevel Stock analysis, traders can create a robust methodology for identifying Cerevel entry and exit points for their positions.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 258 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cerevel Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |